India-like New Broader Compulsory Licensing Provisions in China Could Make the Global Pharma Players Edgy

Quite close on the heel of grant of Compulsory License (CL) to Bayer AG’s expensive Kidney and Liver cancer drug Sorafenib to the domestic Indian manufacturer Natco by the Indian Patent Office, as provided in the Indian Patent Law, China … Continue reading

EU-FTA, TRIPS-Plus provisions, Data Exclusivity, Public Interest and India

Business Standard in its January 27, 2011 edition reported, “Data Exclusivity still key hurdle to India-EU FTA” Before deliberating on this important issue of “Free Trade Agreement (FTA)”, let me touch upon very briefly, for the benefit of all concerned, … Continue reading